炎症性关节病患者他汀治疗期间临床前心脏器官损害:RORA-AS他汀干预研究
本研究纳入84例无已知心血管疾病的炎症性关节病患者,在瑞舒伐他汀治疗18个月前后进行超声心动图检查。结果显示瑞舒伐他汀治疗未显著影响临床前心脏器官损害(基线44% vs 随访50%,P=0.42),但随访时使用bDMARDs与较低的临床前心脏器官损害风险相关。
要点
- 瑞舒伐他汀治疗18个月未显著减少IJD患者临床前心脏器官损害。
- 随访时使用bDMARDs与临床前心脏器官损害风险降低相关(OR 0.3)。
- 基线存在心脏器官损害和较高BMI增加随访时心脏器官损害风险。
核心结论
- 瑞舒伐他汀治疗18个月与IJD患者临床前心脏器官损害减少无关。
- 随访时使用bDMARDs与较低的临床前心脏器官损害风险相关,提示bDMARDs可能具有心脏保护作用。
研究设计与样本
- 研究纳入84例炎症性关节病患者(52例RA,20例强直性脊柱炎,12例银屑病关节炎),平均年龄61(9)岁,63%为女性,无已知心血管疾病。
- 患者在瑞舒伐他汀治疗18个月前后进行超声心动图检查,临床前心脏器官损害定义为左心室肥厚、左心室同心几何构型、左心室腔增大和/或左心房扩张。
主要发现
- 基线时63%患者有高血压,36%使用bDMARDs。
- 瑞舒伐他汀治疗未影响临床前心脏器官损害(基线44% vs 随访50%,P=0.42)。
- 随访时临床前心脏器官损害风险随基线BMI升高而增加(OR 1.3,95%CI:1.1,1.5,P=0.01),随基线存在临床前心脏器官损害而增加(OR 6.4,95%CI:2.2,18.5,P=0.001),随随访时使用bDMARDs而降低(OR 0.3,95%CI:0.1,0.9,P=0.03)。
关键数值与推荐
- 临床前心脏器官损害通过超声心动图识别,包括左心室肥厚、左心室同心几何构型、左心室腔增大和/或左心房扩张。
- 主要比较为瑞舒伐他汀治疗18个月前后临床前心脏器官损害的比例(44% vs 50%,P=0.42)。
临床怎么用
- 对于IJD患者,瑞舒伐他汀治疗18个月未显示减少临床前心脏器官损害,不应仅以此为目的使用他汀。
- 使用bDMARDs可能与较低的临床前心脏器官损害风险相关,临床决策时可综合考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Statin treatment has been associated with reduction in blood pressure and arterial stiffness in patients with inflammatory joint diseases (IJD). We tested whether statin treatment also was associated with regression of preclinical cardiac organ damage in IJD patients. METHODS: Echocardiography was performed in 84 IJD patients (52 RA, 20 ankylosing spondylitis, 12 psoriatric arthritis, mean age 61 (9) years, 63% women) without known cardiovascular disease before and after 18 months of rosuvastatin treatment. Preclinical cardiac organ damage was identified by echocardiography as presence of left ventricular (LV) hypertrophy, LV concentric geometry, increased LV chamber size and/or dilated left atrium. RESULTS: At baseline, hypertension was present in 63%, and 36% used biologic DMARDs (bDMARDs). Preclinical cardiac organ damage was not influenced by rosuvastatin treatment (44% at baseline vs 50% at follow-up, P = 0.42). In uni- and multivariable logistic regression analyses, risk of preclinical cardiac organ damage at follow-up was increased by higher baseline body mass index [odds ratio (OR) 1.3, 95% CI: 1.1, 1.5, P = 0.01] and presence of preclinical cardiac organ damage at baseline (OR 6.4, 95% CI: 2.2, 18.5, P = 0.001) and reduced by use of bDMARDs at follow-up (OR 0.3, 95% CI: 0.1, 0.9, P = 0.03). CONCLUSION: Rosuvastatin treatment was not associated with a reduction in preclinical cardiac organ damage in IJD patients after 18 months of treatment. However, use of bDMARDS at follow-up was associated with lower risk of preclinical cardiac organ damage at study end, pointing to a possible protective cardiac effect of bDMARDs in IJD patients. CLINICALTRIALS.GOV: https://clinicaltrials.gov/NCT01389388.
引用
- Os HA, Rollefstad S, Gerdts E, et al. Preclinical cardiac organ damage during statin treatment in patients with inflammatory joint diseases: the RORA-AS statin intervention study. Rheumatology (Oxford). 2020. PMID: 32386421. doi:10.1093/rheumatology/keaa190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。